Samsung Biologics reappoints CEO John Rim as inside director

By Kim Dong-young Posted : March 20, 2026, 12:12 Updated : March 20, 2026, 12:12
Samsung Biologics holds its 15th annual general shareholder meeting/ Courtesy of Samsung Biologics
 
SEOUL, March 20 (AJP) - Samsung Biologics said Friday that shareholders reappointed Chief Executive John Rim as an inside director at the company's 15th annual general meeting.

About 1,400 shareholders participated in the meeting, which was conducted both on-site and via online livestream. All five agenda items put to a vote were approved as proposed.

In addition to Rim, Executive Vice President Lo Kun, who heads the EPCV Center, was also reappointed as an inside director. Kim Jung-yeon, a professor at Ewha Womans University Law School, was newly appointed as an outside director and audit committee member.

Other approved items included the adoption of financial statements, amendments to the company's articles of incorporation and a cap on executive compensation.

"This year marks our meaningful 15th anniversary," Rim said. "We will continue our efforts to enhance corporate and shareholder value while contributing to the growth of South Korea's bio industry and economy."

Copyright ⓒ Aju Press All rights reserved.